{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:32:59Z","timestamp":1786998779188,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Histochemica"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.acthis.2026.152349","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:29:45Z","timestamp":1780460985000},"page":"152349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["YARS2 mediates PARPi resistance in pancreatic cancer by regulating the MYC-E2F axis"],"prefix":"10.1016","volume":"128","author":[{"given":"Yu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-8461","authenticated-orcid":false,"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib1","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1038\/s41598-018-22673-3","article-title":"Dna is a new target of Parp3","volume":"8","author":"Belousova","year":"2018","journal-title":"Sci. Rep."},{"issue":"7035","key":"10.1016\/j.acthis.2026.152349_bib2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.acthis.2026.152349_bib3","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1535-7163.MCT-21-0841","article-title":"A whole-genome CRISPR screen identifies AHR loss as a mechanism of resistance to a PARP7 inhibitor","volume":"21","author":"Chen","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"25","key":"10.1016\/j.acthis.2026.152349_bib4","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41525-021-00200-0","article-title":"Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy","volume":"6","author":"Dai","year":"2021","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.acthis.2026.152349_bib6","article-title":"Congenital-onset MLASA2 from a novel YARS2 variant: a literature review","author":"Eisenk\u00f6lbl","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"issue":"2","key":"10.1016\/j.acthis.2026.152349_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ijrobp.2009.06.014","article-title":"A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2022.2127603","article-title":"Targeting mitochondrial tyrosyl-tRNA synthetase YARS2 suppresses colorectal cancer progression","volume":"23","author":"Fang","year":"2022","journal-title":"Cancer Biol. & Ther."},{"issue":"6","key":"10.1016\/j.acthis.2026.152349_bib9","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/mc.23705","article-title":"Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer","volume":"63","author":"Furusawa","year":"2024","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12885-020-06903-4","article-title":"Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells","volume":"20","author":"Gil-Kulik","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.acthis.2026.152349_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/cpr.12268","article-title":"The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival","volume":"49","author":"Jubin","year":"2016","journal-title":"Cell. Prolif."},{"key":"10.1016\/j.acthis.2026.152349_bib12","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib13","article-title":"Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"11","author":"Lee","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell. Res."},{"issue":"11","key":"10.1016\/j.acthis.2026.152349_bib15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"issue":"6330","key":"10.1016\/j.acthis.2026.152349_bib16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science (New York N. Y. )"},{"issue":"6","key":"10.1016\/j.acthis.2026.152349_bib17","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/s41418-019-0475-6","article-title":"ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb\/E2F1\/c-Myc-mediated cancer stemness","volume":"27","author":"Luo","year":"2020","journal-title":"Cell. death Differ."},{"issue":"3","key":"10.1016\/j.acthis.2026.152349_bib18","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e44","article-title":"PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies","volume":"33","author":"Miller","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.acthis.2026.152349_bib19","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.acthis.2026.152349_bib20","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2023.34.e25","article-title":"Interleukin-34 cancels anti-tumor immunity by PARP inhibitor","volume":"34","author":"Nakamura","year":"2023","journal-title":"J. Gynecol. Oncol."},{"issue":"46","key":"10.1016\/j.acthis.2026.152349_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp6567","article-title":"USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity","volume":"10","author":"Nespolo","year":"2024","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.acthis.2026.152349_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Mol. Cell."},{"issue":"9","key":"10.1016\/j.acthis.2026.152349_bib23","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/cas.15477","article-title":"Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes","volume":"113","author":"Onji","year":"2022","journal-title":"Cancer Sci."},{"issue":"20","key":"10.1016\/j.acthis.2026.152349_bib24","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1158\/0008-5472.CAN-24-4751","article-title":"PCBP2 mediates olaparib resistance in breast cancer by inhibiting m6A methylation to stabilize PARP1 mRNA","volume":"85","author":"Qi","year":"2025","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.acthis.2026.152349_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/humu.22098","article-title":"A novel mutation in YARS2 causes myopathy with lactic acidosis and sideroblastic anemia","volume":"33","author":"Sasarman","year":"2012","journal-title":"Human. Mutat."},{"issue":"12","key":"10.1016\/j.acthis.2026.152349_bib26","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell."},{"issue":"38","key":"10.1016\/j.acthis.2026.152349_bib27","doi-asserted-by":"crossref","first-page":"45259","DOI":"10.1021\/acsami.1c12725","article-title":"Reversing multidrug resistance by inducing mitochondrial dysfunction for enhanced chemo-photodynamic therapy in tumor","volume":"13","author":"Shi","year":"2021","journal-title":"ACS Appl. Mater. & Interfaces"},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib28","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA a cancer journal clinicians"},{"issue":"6","key":"10.1016\/j.acthis.2026.152349_bib29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamaneurol.2016.4357","article-title":"Clinical features, molecular heterogeneity, and prognostic implications in YARS2-related mitochondrial myopathy","volume":"74","author":"Sommerville","year":"2017","journal-title":"JAMA Neurol."},{"issue":"18","key":"10.1016\/j.acthis.2026.152349_bib30","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13048-025-01641-2","article-title":"MEOX2 mediates cisplatin resistance in ovarian cancer via E2F target and DNA repair pathways","volume":"18","author":"Wang","year":"2025","journal-title":"J. ovarian Res."},{"issue":"7","key":"10.1016\/j.acthis.2026.152349_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jcmm.18213","article-title":"Unveiling the role of YARS1 in bladder cancer: a prognostic biomarker and therapeutic target","volume":"28","author":"Wang","year":"2024","journal-title":"J. Cell. Mol. Med."},{"issue":"7","key":"10.1016\/j.acthis.2026.152349_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41419-021-03921-3","article-title":"LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Cell. death & Dis."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s13287-022-03162-x","article-title":"Haptoglobin is an early indicator of survival after radiation-induced severe injury and bone marrow transplantation in mice","volume":"13","author":"Zhou","year":"2022","journal-title":"Stem Cell. Res. & Ther."},{"issue":"1","key":"10.1016\/j.acthis.2026.152349_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol. Cancer"}],"container-title":["Acta Histochemica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128126000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065128126000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:57:07Z","timestamp":1786996627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065128126000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0065128126000346"],"URL":"https:\/\/doi.org\/10.1016\/j.acthis.2026.152349","relation":{},"ISSN":["0065-1281"],"issn-type":[{"value":"0065-1281","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"YARS2 mediates PARPi resistance in pancreatic cancer by regulating the MYC-E2F axis","name":"articletitle","label":"Article Title"},{"value":"Acta Histochemica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acthis.2026.152349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152349"}}